Teleflex
TFX
$136.58
+4.74%
Teleflex Incorporated is a global medical technology company that designs, develops, and manufactures single-use medical devices for hospitals and healthcare providers, spanning vascular access, anesthesia and emergency medicine, interventional cardiology and radiology, surgical instruments, and interventional urology through its UroLift system, organized across Americas, EMEA, and Asia reporting segments. It occupies a mid-cap niche position in the medical instruments and supplies industry, distinguished less by scale than by a portfolio of high-acuity procedural products with entrenched hospital relationships and recurring consumable revenue. The current investor narrative is dominated by a contested turnaround and strategic-review story: an activist investor has publicly pressured the board to explore a sale, a potential buyout offer briefly sent shares surging in April 2026, and management has been reshaping the portfolio through divestitures and debt paydown after a deeply loss-impairing fiscal 2025. Debate now centers on whether the restructuring and cost discipline can restore durable earnings growth, or whether the ultimate value unlock is a sale of the company, with the stock's muted relative performance reflecting lingering skepticism about organic growth.…
TFX
Teleflex
$136.58
Related headlines
Investment Opinion: Should I buy TFX Today?
Rating: Hold. The core thesis is that TFX is a deep-value turnaround with a potential sale catalyst, but the 27% revenue decline and negative net income make the risk/reward balanced at best. The analyst consensus is 'buy' with an average target of $154, implying 18.1% upside, but the low target of $138 suggests limited downside protection. Supporting evidence includes a forward PE of 11.9x, which is cheap relative to the market, and a PEG ratio of 0.004, though the latter is distorted by near-zero growth. Free cash flow of $390.6 million provides a 7.2% FCF yield, and the current ratio of 2.54 is healthy. However, EV/EBITDA of 25.7x is rich for a declining business, and the 27% revenue drop is a major red flag. The biggest risks are a failed sale process, continued revenue erosion, and high leverage. The rating would upgrade to Buy if revenue stabilizes or a credible buyout emerges above $150, and downgrade to Sell if revenue declines persist below $500 million per quarter or if the forward EPS estimate is cut. Relative to its own history, the stock is cheap on forward earnings but expensive on EBITDA; relative to peers, it trades at a discount on PE but a premium on EV/EBITDA. Overall, the stock appears fairly valued to slightly undervalued on forward earnings, but the uncertainty warrants a Hold.
Sign up to view all
TFX 12-Month Price Forecast
The forward-looking view is balanced. On the positive side, the stock is cheap on forward earnings, generates strong free cash flow, and has a potential sale catalyst. On the negative side, revenue is collapsing, the company is loss-making, and leverage is high. The base case (50% probability) assumes gradual stabilization and a target range of $138-$154. The bull case (25%) hinges on a sale, while the bear case (25%) assumes continued deterioration. I would upgrade to bullish if revenue growth turns positive or a credible buyout emerges, and downgrade to bearish if revenue declines accelerate or interest coverage deteriorates further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Teleflex's 12-month outlook, with a consensus price target around $154.00 and implied upside of +12.8% versus the current price.
Average Target
$154.00
0 analysts
Implied Upside
+12.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$138 - $170
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: TFX Investment Factors
The bear case currently has stronger evidence: revenue is collapsing at 27% YoY, the company is loss-making on a TTM basis, and leverage is high. However, the bull case rests on a potential sale, deep-value forward multiples, and strong free cash flow. The single most important tension is whether the revenue decline is a temporary result of divestitures or a sign of structural weakness; if organic growth returns, the stock could re-rate sharply, but if the decline persists, the forward EPS estimate of $14.24 will be at risk.
Bullish
- Deep value on forward earnings: At $130.43, TFX trades at just 11.9x forward EPS of $14.24, a steep discount to the broader market and to its own historical multiple. The PEG ratio of 0.004 (albeit distorted by near-zero growth) and price-to-sales of 2.73x suggest the market is pricing in little recovery. If earnings normalize, multiple expansion alone could drive significant upside.
- Analyst targets imply 18% upside: The 11-analyst consensus is 'buy' with an average target of $154, 18.1% above the current price. The low target of $138 is still 5.8% above the current price, indicating that even the most cautious analysts see limited downside from here. The high target of $170 implies 30.3% upside.
- Strong free cash flow and liquidity: TTM free cash flow is $390.6 million, a 7.2% FCF yield on the $5.35 billion market cap. The current ratio of 2.54 is healthy, and debt-to-equity of 0.87 is manageable for a medtech company. This cash generation supports debt paydown and potential buybacks.
- Activist pressure and buyout potential: An activist investor is publicly urging the board to explore a sale, and a potential buyout offer in April 2026 caused the stock to surge over 8% in pre-market trading. This creates a floor on the stock and a potential catalyst for a re-rating if a deal materializes.
Bearish
- Revenue collapsing at 27% YoY: Q2 2026 revenue fell 27.0% year-over-year to $570.3 million, a severe contraction that raises questions about the sustainability of the business. This decline is likely due to divestitures, but organic growth remains unclear and the top-line pressure is intense.
- Net loss and negative ROE: TTM net margin is -45.4% and ROE is -29.0%, reflecting the massive impairment charges in fiscal 2025. The company reported a net loss of $714 million in Q4 2025 alone, wiping out shareholder equity and leaving trailing EPS at -$0.17.
- High leverage and interest burden: Debt-to-equity is 0.87, and interest expense was $28.0 million in Q2 2026, consuming 46% of operating income. With EBITDA of only $73.1 million in Q2, the interest coverage ratio is just 2.6x, leaving little room for error if earnings decline further.
- Relative underperformance vs. market: TFX has underperformed the S&P 500 by 10.2 percentage points over the past year and by 5.4 points YTD, with a beta of 0.83. The stock's 1-year return of 5.3% lags the market's 15.5%, reflecting investor skepticism about the turnaround.
TFX Technical Analysis
Beta
0.83
0.83x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$100-$145
Price range past year
Annual Return
+2.9%
Cumulative gain past year
| Period | TFX Return | S&P 500 |
|---|---|---|
| 1m | +9.4% | -1.2% |
| 3m | +3.4% | +3.4% |
| 6m | +0.0% | +7.0% |
| 1y | +2.9% | +14.4% |
| ytd | +11.6% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TFX Fundamental Analysis
Quarterly Revenue
$570332000.0B
2026-06
Revenue YoY Growth
-27.0%
YoY Comparison
Gross Margin
58.2%
Latest Quarter
Free Cash Flow
$390632000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TFX Overvalued?
PE
-6.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. Revenue fell 27.0% YoY in Q2 2026 to $570.3 million, and TTM net margin is -45.4% with a net loss of $714 million in Q4 2025. Debt-to-equity is 0.87, and interest expense of $28.0 million consumed 46% of operating income in Q2, leaving interest coverage at just 2.6x EBITDA. The company's ability to service debt depends on a rapid earnings recovery that is not yet evident. Market and competitive risks include valuation compression if the turnaround stalls. EV/EBITDA is 25.7x, well above typical medtech levels, and the stock has underperformed the S&P 500 by 10.2 percentage points over the past year. Beta is 0.83, indicating lower market correlation, but sector rotation away from healthcare and competitive pressures in vascular access and urology could weigh on growth. The activist campaign and buyout speculation add event risk; if no deal materializes, the stock could give back its April gains. The worst-case scenario is a failed sale process combined with continued revenue decline, which could push the stock toward its 52-week low of $100.18, a 23.2% decline from the current $130.43. With a max drawdown of -24.6% over the past 180 days, investors could lose over 20% in a adverse scenario. The analyst low target of $138 offers some support, but if forward EPS estimates are cut, the stock could break below $100.
FAQ
The most severe risk is continued revenue decline: Q2 2026 revenue fell 27% YoY, and if this persists, forward EPS estimates will be cut. Financial risk is high with debt-to-equity of 0.87 and interest coverage of only 2.6x, leaving little cushion. Competitive and market risks include a failed sale process, which could cause the stock to retest its 52-week low of $100.18, and sector rotation away from healthcare. Company-specific risks include the activist campaign not achieving a sale and potential loss of key contracts. Ranked by severity: revenue decline, leverage, failed sale, and competitive pressures.
The 12-month forecast has three scenarios: bull (25% probability) with a target range of $154-$170, driven by a sale or buyout; base (50%) with a range of $138-$154, assuming gradual stabilization; and bear (25%) with a range of $100-$138, assuming continued revenue decline. The most likely scenario is the base case, which assumes revenue declines moderate and margins improve modestly, leading to a stock price around the analyst average target of $154. The key assumption is that the company successfully executes its restructuring and avoids further earnings deterioration.
On forward earnings, TFX appears undervalued at 11.9x forward EPS of $14.24, well below the market average. However, on EV/EBITDA, it is expensive at 25.7x, reflecting the depressed EBITDA base. The trailing PE is negative due to impairments, and the PEG ratio of 0.004 is distorted by near-zero growth. Relative to its own history, the forward PE is near multi-year lows, suggesting the market is pricing in significant skepticism. The stock is fairly valued to slightly undervalued if earnings normalize, but the high EV/EBITDA multiple implies the market expects a strong recovery. Overall, the valuation is a bet on a turnaround rather than a clear bargain.
TFX is a high-risk, high-reward contrarian bet. The stock trades at 11.9x forward EPS, a steep discount to the market, and analysts have a 'buy' consensus with an average target of $154, implying 18.1% upside. However, revenue fell 27% YoY in Q2 2026, and the company is loss-making on a TTM basis, so the downside risk is significant. The biggest risk is a failed sale process and continued revenue decline, which could push the stock to its 52-week low of $100.18, a 23% drop. For investors with a long horizon and tolerance for volatility, a small position could be justified, but it is not a good buy for conservative portfolios.
TFX is more suitable for medium-term special-situation investing than for long-term compounding. The stock has a beta of 0.83, lower volatility than the market, but the turnaround story is event-driven (sale process, activist pressure). The dividend yield is 1.1%, providing minimal income. Earnings visibility is low due to the 27% revenue decline and restructuring. A suggested holding period is 12-18 months, enough time for the strategic review to conclude and for revenue trends to become clearer. Short-term trading is risky given the binary nature of the sale catalyst. Long-term investors should wait for evidence of sustainable organic growth before committing.